
R&D
CAR-T cell therapy technology development strategy
Development of CAR Pool platform for antibody genes by utilizing AI technology
Development of treatment for refractory diseases and product approval of 7 types (Blood cancer,
pancreatic cancer, Liver cancer, Lung cancer, Autoimmune disease, Dementia, combination therapy, etc.)
Priority development of CAR-T cells targeting blood cancer
-
Hematological cancer treatment based on Next-generation CAR-T
-
Rapid Clinical trial entry to validate the Safety & Efficacy of CAR-T treatment
-
Optimization of dosage and route of administration of CAR-T cells
-
Expand application to Solid cancer with the same CAR-T
Development of Next-generation CAR-T that overcomes Cancer Microenvironment and minimizes side effects
Allogeneic CAR for immediate treatment in emergency situations
Development of CAR that can be used for T cells and NK cells
Easily accessible CAR: 'Off-the-Shelf' Uni-CAR
-
Introduce cytokines that can break the immunosuppressive environment and strongly induce immune activity (Cy-CAR)
-
Minimize side effects by binding to cancer-targeting proteins and secreting cytokines around cancer cells
-
Development of CAR-T (Home CAR) that can greatly move to cancer tissue

CarBio Therapeutics develops anti-cancer CAR-T immune cell therapy for patients suffering from serious diseases
Strategy

CAR-T
Platform
(TKI, Tyrosine Kinase inhibitor)
CAR-T cell therapy technology development strategy
Development of CAR Pool platform for antibody genes by utilizing AI technology
Development of treatment for refractory diseases and product approval of 7 types (Blood cancer,
pancreatic cancer, Liver cancer, Lung cancer, Autoimmune disease, Dementia, combination therapy, etc.)
Priority development of CAR-T cells targeting blood cancer
-
Hematological cancer treatment based on Next-generation CAR-T
-
Rapid Clinical trial entry to validate the Safety & Efficacy of CAR-T treatment
-
Optimization of dosage and route of administration of CAR-T cells
-
Expand application to Solid cancer with the same CAR-T
Development of Next-generation CAR-T that overcomes Cancer Microenvironment and minimizes side effects
Allogeneic CAR for immediate treatment in emergency situations
Development of CAR that can be used for T cells and NK cells
Easily accessible CAR: 'Off-the-Shelf' Uni-CAR
-
Introduce cytokines that can break the immunosuppressive environment and strongly induce immune activity (Cy-CAR)
-
Minimize side effects by binding to cancer-targeting proteins and secreting cytokines around cancer cells
-
Development of CAR-T (Home CAR) that can greatly move to cancer tissue
